Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

HSBC and Asian Development Bank join forces in $300 million vaccine financing

Published 04/08/2021, 07:16 PM
Updated 04/08/2021, 07:20 PM
© Reuters. FILE PHOTO: Workers place Sinovac COVID-19 vaccine vials in trays at Butantan biomedical production center

© Reuters. FILE PHOTO: Workers place Sinovac COVID-19 vaccine vials in trays at Butantan biomedical production center

LONDON (Reuters) - HSBC and the Asian Development Bank (ADB) will provide a combined $300 million in financing to help Asia's supply chains boost manufacturing capacity for COVID-19 vaccines, the two lenders said on Friday.

The initiative builds on a risk-sharing scheme the banks launched in July to help to fund suppliers of personal protective equipment (PPE) as they and vaccine makers race to meet global demand that outstrips supply.

By leaning on the ADB's sovereign-level credit rating, private sector lenders such as HSBC can lend more easily to companies in the complex chain of vaccine supply production, HSBC said.

"Right now demand for vaccines far outstrips supply and one of the challenges is that supply and distribution networks have to be formed, which requires a lot of liquidity," said Surath Sengupta, global head of financial institutions at HSBC.

The lenders will offer funds through trade loans and invoice financing among other tools, Sengupta said, as countries across Asia try to shorten the usual multi-year time scale needed to deploy large-scale inoculation programmes.

Vaccination levels in Asian countries have varied widely as governments deal with limited supplies, rapidly rising demand and political jockeying to secure doses.

© Reuters. FILE PHOTO: Workers place Sinovac COVID-19 vaccine vials in trays at Butantan biomedical production center

Leaders of the United States, India, Australia and Japan agreed to pool financing, manufacturing and distribution capacity to send 1 billion coronavirus vaccines across Asia by the end of 2022, India's foreign secretary said in March.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.